$heff's $tation of $tocks & $olid DD

[pmony5]

ADMP Adamis Pharma defended premarket at CRT Capital (5.60 +0.00)
CRT Capital believes yesterday's weakness in ADMP was tied to the restructuring of their remaining $600K convert -- given the extended maturity and lower strike the perception is that they don't have enough cash to pay it off, but this is untrue. With $7 mln in cash and a $240K/month burn rate, co has ample cash for this year. The fundamentals are unchanged and firm continues to highlight their solid respiratory franchise plus free option on their epinephrine pre-filled syringe. The EpiPen comp is a huge opportunity -- with filing by the end of this month and potential approval by year end, even a sliver of the anaphylaxis market makes the stock a double.